Pfizer Stock Price, News & Analysis (NYSE:PFE)

$36.26 +0.52 (+1.45 %)
(As of 02/25/2018 04:26 AM ET)
Previous Close$36.26
Today's Range$35.83 - $36.30
52-Week Range$31.67 - $39.43
Volume16.00 million shs
Average Volume28.58 million shs
Market Capitalization$216.14 billion
P/E Ratio20.72
Dividend Yield3.75%
Beta0.94

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:PFE
CUSIP71708110
Phone+1-212-5732323

Debt

Debt-to-Equity Ratio0.56%
Current Ratio1.43%
Quick Ratio1.15%

Price-To-Earnings

Trailing P/E Ratio20.72
Forward P/E Ratio12.29
P/E Growth2.02

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.11
Cash Flow$3.55 per share
Price / Cash10.22
Book Value$9.86 per share
Price / Book3.68

Profitability

Trailing EPS$1.75
Net Income$21.31 billion
Net Margins40.55%
Return on Equity26.86%
Return on Assets9.44%

Miscellaneous

Employees96,500
Outstanding Shares5,952,870,000

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 18th. Stockholders of record on Friday, February 2nd will be given a dividend of $0.34 per share on Thursday, March 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. The ex-dividend date is Thursday, February 1st. This is a boost from Pfizer's previous quarterly dividend of $0.32. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has authorized a share repurchase program on Tuesday, December 19th 2017, which authorizes the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Tuesday, January, 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.56 by $0.06. The biopharmaceutical company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the business earned $0.47 earnings per share. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY18 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.78. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $53.82 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2018?

18 Wall Street analysts have issued twelve-month price targets for Pfizer's shares. Their predictions range from $31.00 to $43.00. On average, they anticipate Pfizer's share price to reach $39.29 in the next twelve months. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. According to Zacks Investment Research, "Pfizer is working on strengthening its product portfolio through acquisitions and licensing deals. Pfizer faces headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. Pfizer has a mixed record of earnings surprises in recent quarters. Estimates have gone up slightly ahead of its Q4 earnings release." (1/24/2018)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 3. UBS Group AG analysts commented, " The FDA approved Novartis' CDK4/6 agent, Kisqali (ribociclib), in first-line treatment for HR+/HER2- metastatic breast cancer in combo with any aromatase inhibitor. Recall that MONALEESA-2 was stopped early, and while interim data demonstrated a reduction in risk of disease progression or death by 44% over letrozole alone, the mPFS had not been reached at the time. For the first time, the label presented a mPFS of 25.3 mos for Kisqali + letrozole vs 16 mos for letrozole alone. The 9.3 mos improvement over letrozole is essentially comparable to 10.3 mos improvement (24.8 mos for Ibrance vs 14.5 mos for letrozole) for Pfizer's Ibrance. Given the strong interim data that were comparable to Ibrance, we believe the approval of Kisqali was largely expected. Our takeaway: Label looks a little worse than Ibrance. Overall, we think the label looks slightly worse, particularly on safety. On the positive, the label is broader, as the indication is for use of Kisqali in combo with anyaromatase inhibitors (vs Ibrance in combo with letrozole). However, as the vast majority of first-line use letrozole, the broader label shouldn't meaningfully impact Ibrance, in our view. We're not clear on how Kisqali got the broader label, but we think this could be encouraging for Ibrance, as the Ibrance label could also become as broad with the potential April approval of the confirmatory Phase 3 PALOMA-2 (Ibrance was approved under an accelerated pathway with Phase 2 PALOMA-1 data). On safety, the Kisqali label warns of QT prolongation and liver tox, which are not in the Ibrance label. We think the QT issue could put Kisqali at a disadvantage. Thoughts on the stock: Shouldn't impact the stock much, if anyIbrance has been on the market for ~2 years and has made significant headway to becoming a standard of therapy, and we do not believe there was anything in the Kisqali label that would meaningfully impact the significant lead that Pfizer has. In our CDK4/6 model, we assign a 5% share for Kisqali in 2017 that goes to 15%, 18%, and 20% in 2018-2020E." (3/14/2017)

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 56,963,145 shares, an increase of 9.2% from the January 12th total of 52,176,014 shares. Based on an average trading volume of 28,232,327 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.0% of the company's stock are sold short.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer (Age 63)
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations (Age 59)
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development (Age 58)
  • Angela Hwang, Group President - Pfizer Essential Health (Age 52)
  • John D. Young, Group President - Pfizer Innovative Health and Angela Hwang (Age 53)
  • Albert Bourla, Chief Operating Officer (Age 56)
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer (Age 55)
  • Douglas M. Lankler, Executive Vice President, General Counsel (Age 51)
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources (Age 61)
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer (Age 62)

Who owns Pfizer stock?

Pfizer's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.60%), Bank of New York Mellon Corp (1.19%), Geode Capital Management LLC (1.06%), Franklin Resources Inc. (0.76%), Barrow Hanley Mewhinney & Strauss LLC (0.71%) and Fisher Asset Management LLC (0.61%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, Renaissance Technologies LLC, Pentwater Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, Metropolitan Life Insurance Co. NY, Assenagon Asset Management S.A., The Manufacturers Life Insurance Company and ING Groep NV. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Frank A Damelio, Ian C Read, Laurie J Olson, Mikael Dolsten, Rady A Johnson and Sally Susman. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Mackenzie Financial Corp, Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, American Century Companies Inc., Sanders Capital LLC, MUFG Securities EMEA plc and Geode Capital Management LLC. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $36.26.

How big of a company is Pfizer?

Pfizer has a market capitalization of $216.14 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $1.75 on an earnings per share basis. Pfizer employs 96,500 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 E 42ND ST, NEW YORK, NY 10017-5703, United States. The biopharmaceutical company can be reached via phone at +1-212-5732323.


MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  935 (Vote Outperform)
Underperform Votes:  494 (Vote Underperform)
Total Votes:  1,429
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfizer (NYSE:PFE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyHold
Consensus Rating Score: 2.392.502.532.44
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $39.29$37.79$38.60$37.94
Price Target Upside: 10.16% upside2.62% upside8.76% upside14.13% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018BMO Capital MarketsSet Price TargetBuy$43.00LowView Rating Details
1/31/2018BarclaysBoost Price TargetOverweight -> Overweight$38.00 -> $41.00MediumView Rating Details
1/31/2018Credit Suisse GroupBoost Price TargetNeutral -> Neutral$37.00 -> $39.00MediumView Rating Details
1/31/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$35.00 -> $38.00MediumView Rating Details
1/31/2018Morgan StanleyBoost Price TargetOverweight -> Buy$41.00 -> $43.00MediumView Rating Details
1/31/2018Societe GeneraleSet Price TargetNeutral$40.00MediumView Rating Details
1/30/2018Goldman Sachs GroupSet Price TargetNeutral$36.00HighView Rating Details
1/30/2018MorningstarSet Price TargetNeutral$38.00HighView Rating Details
1/30/2018Bank of AmericaSet Price TargetBuy$40.00MediumView Rating Details
1/30/2018JPMorgan Chase & Co.Reiterated RatingBuyLowView Rating Details
1/30/2018Sanford C. BernsteinSet Price TargetBuy$43.00LowView Rating Details
1/30/2018Berenberg BankSet Price TargetNeutral$36.00LowView Rating Details
1/29/2018SunTrust BanksReiterated RatingHold -> Hold$33.00 -> $40.00LowView Rating Details
1/16/2018Jefferies GroupSet Price TargetNeutral$40.00LowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/6/2017Deutsche BankSet Price TargetBuy$38.00LowView Rating Details
8/14/2017CowenSet Price TargetBuy$43.00LowView Rating Details
5/16/2017CitigroupDowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
5/4/2016Independent ResearchSet Price TargetNeutral$37.00N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$0.70N/AView Earnings Details
1/30/2018Q4 2017$0.56$0.62$13.67 billion$13.70 billionViewListenView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.17 billion$13.17 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.08 billion$12.90 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
11/2/2010Q3 2010$0.51$0.54ViewN/AView Earnings Details
8/3/2010Q2 2010$0.52$0.62ViewN/AView Earnings Details
5/4/2010Q1 2010$0.53$0.60ViewN/AView Earnings Details
2/3/2010Q4 2009$0.49$0.49ViewN/AView Earnings Details
10/20/2009Q3 2009$0.48$0.51ViewN/AView Earnings Details
7/22/2009Q2 2009$0.46$0.48ViewN/AView Earnings Details
4/28/2009Q1 2009$0.48$0.54ViewN/AView Earnings Details
1/26/2009Q4 2008$0.60$0.65ViewN/AView Earnings Details
10/21/2008Q3 2008$0.60$0.62ViewN/AView Earnings Details
7/23/2008Q2 2008$0.54$0.55ViewN/AView Earnings Details
4/17/2008Q1 2008$0.65$0.61ViewN/AView Earnings Details
1/23/2008Q4 2007$0.47$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pfizer (NYSE:PFE) Earnings Estimates

2018 EPS Consensus Estimate: $2.94
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.67$0.67$0.67
Q2 20181$0.70$0.70$0.70
Q3 20181$0.75$0.75$0.75
Q4 20181$0.82$0.82$0.82
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Pfizer (NYSE:PFE) Dividend Information

Next Dividend:3/1/2018
Annual Dividend:$1.36
Dividend Yield:3.75%
Dividend Growth:7.20% (3 Year Average)
Payout Ratio:77.71% (Trailing 12 Months of Earnings)
46.10% (Based on This Year's Estimates)
44.88% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/18/2017quarterly$0.343.68%2/1/20182/2/20183/1/2018
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 70.12%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Alexander R MackenzieInsiderSell6,750$37.00$249,750.00103,458View SEC Filing  
12/15/2017Rady A JohnsonEVPSell8,000$37.07$296,560.0046,963View SEC Filing  
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00117,432View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50117,432View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00145,649View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00124,774View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00132,124View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00337,389View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00580,318View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.8074,506View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00151,474View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.0054,963View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.0057,329View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.7064,719View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00112,087View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50149,199View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00472,994View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00271,663View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.0071,659View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00564,994View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00200,399View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.5088,922View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.001,446,738View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00195,951View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00124,920View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48438,107View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35372,994View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.0099,647View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15171,756View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62344,571View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15173,637View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20356,451View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70118,383View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
Better Buy: Novavax, Inc. vs. Pfizer Inc. - Motley FoolBetter Buy: Novavax, Inc. vs. Pfizer Inc. - Motley Fool
www.fool.com - February 24 at 3:34 PM
First Republic Investment Management Inc. Has $109.64 Million Holdings in Pfizer Inc. (PFE)First Republic Investment Management Inc. Has $109.64 Million Holdings in Pfizer Inc. (PFE)
www.americanbankingnews.com - February 24 at 4:28 AM
Oppenheimer Asset Management Inc. Buys 69,202 Shares of Pfizer Inc. (PFE)Oppenheimer Asset Management Inc. Buys 69,202 Shares of Pfizer Inc. (PFE)
www.americanbankingnews.com - February 24 at 4:28 AM
Pfizer Inc. (PFE) Shares Sold by Heritage Trust CoPfizer Inc. (PFE) Shares Sold by Heritage Trust Co
www.americanbankingnews.com - February 24 at 4:27 AM
Pfizer Inc. (PFE) Shares Sold by M&R Capital Management Inc.Pfizer Inc. (PFE) Shares Sold by M&R Capital Management Inc.
www.americanbankingnews.com - February 24 at 4:27 AM
Saturna Capital CORP Increases Stake in Pfizer Inc. (PFE)Saturna Capital CORP Increases Stake in Pfizer Inc. (PFE)
www.americanbankingnews.com - February 24 at 4:26 AM
Segall Bryant & Hamill LLC Trims Position in Pfizer Inc. (PFE)Segall Bryant & Hamill LLC Trims Position in Pfizer Inc. (PFE)
www.americanbankingnews.com - February 24 at 4:26 AM
Pfizer Inc. (PFE) Shares Bought by Uniplan Investment Counsel Inc.Pfizer Inc. (PFE) Shares Bought by Uniplan Investment Counsel Inc.
www.americanbankingnews.com - February 24 at 4:26 AM
Pfizer Inc. (PFE) Stake Lowered by Apriem AdvisorsPfizer Inc. (PFE) Stake Lowered by Apriem Advisors
www.americanbankingnews.com - February 24 at 4:24 AM
Carret Asset Management LLC Grows Position in Pfizer Inc. (PFE)Carret Asset Management LLC Grows Position in Pfizer Inc. (PFE)
www.americanbankingnews.com - February 24 at 4:24 AM
Pfizer (PFE) a Hold at $35.77 - Investorplace.comPfizer (PFE) a Hold at $35.77 - Investorplace.com
investorplace.com - February 23 at 3:34 PM
Analysts’ Post-4Q17 Recommendations for Eli LillyAnalysts’ Post-4Q17 Recommendations for Eli Lilly
finance.yahoo.com - February 23 at 3:34 PM
Albert Bourla Elected to Pfizer’s Board of DirectorsAlbert Bourla Elected to Pfizer’s Board of Directors
finance.yahoo.com - February 23 at 10:51 AM
Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®
finance.yahoo.com - February 23 at 10:51 AM
Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell CarcinomaPfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
finance.yahoo.com - February 23 at 10:51 AM
Correction: Tax Overhaul-Company Spending storyCorrection: Tax Overhaul-Company Spending story
marketbeat.com - February 22 at 3:16 PM
Pfizer (PFE) a Hold at $35.77Pfizer (PFE) a Hold at $35.77
investorplace.com - February 22 at 1:15 PM
Would Pfizer Investors Win With a Bristol-Myers Squibb Acquisition?Would Pfizer Investors Win With a Bristol-Myers Squibb Acquisition?
www.fool.com - February 22 at 6:22 AM
GlaxoSmithKline’s Vaccines Business in 4Q17GlaxoSmithKline’s Vaccines Business in 4Q17
finance.yahoo.com - February 20 at 10:04 AM
GlaxoSmithKline’s HIV Business in 4Q17GlaxoSmithKline’s HIV Business in 4Q17
finance.yahoo.com - February 19 at 3:34 PM
GlaxoSmithKline’s Pharmaceuticals Business in 4Q17GlaxoSmithKline’s Pharmaceuticals Business in 4Q17
finance.yahoo.com - February 19 at 9:34 AM
Why Healthcare Stocks Soared in Trump's First Year in OfficeWhy Healthcare Stocks Soared in Trump's First Year in Office
finance.yahoo.com - February 18 at 3:32 PM
[$$] Novartis CEO Steers Drug Maker Back to R&D[$$] Novartis CEO Steers Drug Maker Back to R&D
finance.yahoo.com - February 18 at 9:50 AM
This High-Yielding Dividend Stock Deserves a Gold MedalThis High-Yielding Dividend Stock Deserves a Gold Medal
finance.yahoo.com - February 17 at 3:37 PM
How Did Pfizer Inc’s (NYSE:PFE) 34.94% ROE Fare Against The Industry?How Did Pfizer Inc’s (NYSE:PFE) 34.94% ROE Fare Against The Industry?
finance.yahoo.com - February 17 at 9:50 AM
Inside Pfizer’s Rare Disease Segment Performance in 2017Inside Pfizer’s Rare Disease Segment Performance in 2017
finance.yahoo.com - February 16 at 10:00 AM
Pfizer (PFE) Given a $43.00 Price Target by BMO Capital Markets AnalystsPfizer (PFE) Given a $43.00 Price Target by BMO Capital Markets Analysts
www.americanbankingnews.com - February 15 at 5:06 PM
Merck KGaA and Pfizers Avelumab fails in trialMerck KGaA and Pfizer's Avelumab fails in trial
www.marketwatch.com - February 15 at 3:38 PM
Behind Pfizer’s Sterile Injection Pharmaceutical Performance in 2017Behind Pfizer’s Sterile Injection Pharmaceutical Performance in 2017
finance.yahoo.com - February 15 at 3:38 PM
6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock)6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock)
finance.yahoo.com - February 15 at 3:38 PM
Pfizer (PFE) Reports Breakthrough Therapy Designation from FDA for PF-04965842Pfizer (PFE) Reports Breakthrough Therapy Designation from FDA for PF-04965842
www.streetinsider.com - February 15 at 5:34 AM
Pfizer (PFE) Reports Breakthrough Therapy Designation from FDA ... - StreetInsider.comPfizer (PFE) Reports Breakthrough Therapy Designation from FDA ... - StreetInsider.com
www.streetinsider.com - February 14 at 3:18 PM
3 Reasons to Be Bullish on Pfizer Inc. Stock - Investorplace.com3 Reasons to Be Bullish on Pfizer Inc. Stock - Investorplace.com
investorplace.com - February 14 at 3:18 PM
With the Correction In Pfizer Behind Us, Traders Can Go Long AgainWith the Correction In Pfizer Behind Us, Traders Can Go Long Again
finance.yahoo.com - February 14 at 3:18 PM
3 Reasons to Be Bullish on Pfizer Inc. Stock3 Reasons to Be Bullish on Pfizer Inc. Stock
investorplace.com - February 14 at 11:39 AM
Where Pfizer Stands in Biosimilars after 2017Where Pfizer Stands in Biosimilars after 2017
finance.yahoo.com - February 14 at 5:31 AM
Merck scraps another late-stage Alzheimers drug studyMerck scraps another late-stage Alzheimer's drug study
finance.yahoo.com - February 14 at 5:31 AM
Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY) -- The Motley Fool - Motley FoolBetter Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY) -- The Motley Fool - Motley Fool
www.fool.com - February 13 at 3:17 PM
Pfizer (PFE) Sees Downgrade….. Weak Earnings Momentum - Investorplace.comPfizer (PFE) Sees Downgrade….. Weak Earnings Momentum - Investorplace.com
investorplace.com - February 13 at 3:17 PM
Pfizer Announces FDA Acceptance of NDA for NSCLC CandidatePfizer Announces FDA Acceptance of NDA for NSCLC Candidate
finance.yahoo.com - February 13 at 3:17 PM
Eliquis: Bristol-Myers Squibb’s Cardiovascular Blockbuster in 4Q17Eliquis: Bristol-Myers Squibb’s Cardiovascular Blockbuster in 4Q17
finance.yahoo.com - February 13 at 3:17 PM
Analyzing Pfizer’s Ibrance and Xalkori after 2Q17Analyzing Pfizer’s Ibrance and Xalkori after 2Q17
finance.yahoo.com - February 13 at 3:17 PM
How Pfizer Performed Overall in 4Q17 and 2017How Pfizer Performed Overall in 4Q17 and 2017
finance.yahoo.com - February 13 at 3:17 PM
The Quest to Develop the First Alzheimers Disease TreatmentThe Quest to Develop the First Alzheimer's Disease Treatment
finance.yahoo.com - February 13 at 3:17 PM
Pfizer (PFE) Sees Downgrade….. Weak Earnings MomentumPfizer (PFE) Sees Downgrade….. Weak Earnings Momentum
investorplace.com - February 13 at 12:57 PM
Zacks: Analysts Anticipate Pfizer Inc. (PFE) Will Announce Quarterly Sales of $12.90 BillionZacks: Analysts Anticipate Pfizer Inc. (PFE) Will Announce Quarterly Sales of $12.90 Billion
www.americanbankingnews.com - February 13 at 11:32 AM
Bristol-Myers Squibb’s 4Q17 Earnings PerformanceBristol-Myers Squibb’s 4Q17 Earnings Performance
finance.yahoo.com - February 13 at 5:36 AM
Novartis gains U.S. approval for delayed MS drugNovartis gains U.S. approval for delayed MS drug
finance.yahoo.com - February 13 at 5:36 AM
Short Interest in Pfizer Inc. (PFE) Rises By 9.2%Short Interest in Pfizer Inc. (PFE) Rises By 9.2%
www.americanbankingnews.com - February 13 at 1:58 AM
Pfizer (PFE) Says U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of its Third-Generation ALK Inhibitor LorlatinibPfizer (PFE) Says U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of its Third-Generation ALK Inhibitor Lorlatinib
www.streetinsider.com - February 12 at 3:17 PM

SEC Filings

Pfizer (NYSE:PFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pfizer (NYSE PFE) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.